The global chlamydia infection diagnostics and therapeutics market is envisioned to be pampered by a sturdy demand in the foreseeable future that could rise on the back of growing incidences of the sexually transmitted disease (STD) in emerging countries of Latin America and Asia Pacific. Conversely, the market could also receive a propelling demand due to the surging count of STD cases in developed nations such as the U.S. The latest health data of Annual County Health Rankings has revealed that Idaho’s Canyon County has topped the charts in comparison with its neighboring counties when it comes to new cases of chlamydia. Alaska, however, could be the worst state in the nation with 768.3 new cases per 100,000 statewide, as per the statistics of the Centers for Disease Control and Prevention (CDC).
The global chlamydia infection diagnostics and therapeutics market could also expect new opportunities birthing from the introduction of new diagnostic techniques. For instance, a San Rafael, California non-profit has come up with a new rapid human immunodeficiency virus (HIV) test known as ‘fourth generation HIV testing.’ It was offered free on the National HIV Testing Day. According to a report by Transparency Market Research (TMR), the market is projected to progress at a 6.0% CAGR between 2017 and 2025 to achieve a valuation of US$2.0 bn by the concluding forecast year. In 2016, the valuation had reached a US$1.1 bn.
Which Regional Market Secures Winning Share for both Diagnostics and Therapeutics?
North America is researched to be a golden market for chlamydia infection diagnostics and therapeutics, considering its presiding shares in 2016. The region had accounted for a 55.5% share on the part of diagnostics and 44.5% share in view of therapeutics. Public and private health insurance organizations offering well-defined reimbursement policies and the presence of a well-established healthcare sector are prognosticated to help North America take the driver’s seat in the international chlamydia infection diagnostics and therapeutics market. Proactive initiatives forwarded by public and private bodies to increase awareness about the STD has led to the availability of healthier diagnostic and treatment rates.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8212
Which Diagnostic and Therapeutic Products Promise Commanding Growth?
The perpetual escalation in the count of diagnosed chlamydia cases could be for the reason that there is more focus on the testing of asymptomatic people with larger sensitivity and employment of extensive diagnostic tests. This is evident of the preference shift to nucleic acid amplification tests (NAATs) from culture-based methods. In 2016, direct fluorescent tests had narrowly followed NAATs on the basis of growth. However, NAATs are prophesied to bear a higher share in the world chlamydia infection diagnostics market but at a reasonable CAGR.
Antibiotics such as macrolides and tetracycline could be key for the demand in the world chlamydia infection therapeutics market, owing to a greater physician prescription preference for them.